Program
Varenicline
Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.
Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.
Drug pageVarenicline: every studyMany companies study it; this page follows only the 44 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 320 open or running | phase 4since Jan 3, 2008 | Aug 29, 2005 | none ahead |
| Viatrisits history only | 60 open or running | phase 3since Jul 25, 2019 | Aug 15, 2018 | none ahead |
| Corxel Pharmaceuticalsits history only | 20 open or running | phase 3since May 13, 2022 | May 13, 2022 | none ahead |
| Rose Research Centerits history only | 20 open or running | phase 4since Jun 6, 2019 | Jun 6, 2019 | none ahead |
| Kriya Therapeuticsits history only | 11 open or running | phase 2since Apr 17, 2026 | Apr 17, 2026 | Feb 2029phase 2 · NCT07596485 |
| SRI Internationalits history only | 10 open or running | no phasesince Mar 8, 2006 | Mar 8, 2006 | none ahead |
Also a collaborator on its studies: GlaxoSmithKline.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since Aug 29, 2005.
- Jun 8, 2011Phase 4 study in Smoking CessationPfizer · NCT01370356 · 1,510 enrolled · United States, Australia, Canada and more
- Oct 14, 2011Phase 4 study in Smoking CessationPfizer · NCT01456936 · 8,144 enrolled · United States, Argentina, Australia and more
- Apr 6, 2012Phase 4 study in Smoking CessationPfizer · NCT01574703 · 4,595 enrolled · United States, Argentina, Australia and more
- Aug 15, 2018Viatris’s first study: phase 2 study in Dry Eye SyndromesNew to ViatrisViatris · NCT03636061 · 182 enrolled · United States
- Sep 26, 2018Phase 2 study in Dry Eye SyndromesViatris · NCT03688802 · 18 enrolled · United States
- Mar 11, 2019Phase 2 study in Dry Eye SyndromesViatris · NCT03873246 · 123 enrolled · Mexico
- Jun 6, 2019Rose Research Center’s first study: phase 4 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04188106 · 26 enrolled · United States
- Jul 25, 2019Phase 3 study in Dry Eye SyndromesViatris · NCT04036292 · 758 enrolled · United States
- Aug 27, 2019Phase 1 study in Healthy SubjectsViatris · NCT04072146 · 22 enrolled · United States
- Dec 4, 2019Phase 3 study in Smoking CessationRose Research Center · NCT04210180 · 25 enrolled · United States
- Jun 28, 2021Phase 2 study in Neurotrophic KeratopathyViatris · NCT04957758 · 113 enrolled · United States
- May 13, 2022Corxel Pharmaceuticals’ first study: phase 3 study in Dry Eye SyndromesNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT05378945 · 340 enrolled · China
- Sep 27, 2022Phase 1 study in Dry Eye SyndromesCorxel Pharmaceuticals · NCT05576415 · 9 enrolled · China
- Apr 17, 2026Kriya Therapeutics’ first study: phase 2 study in Trigeminal NeuralgiaNew to Kriya TherapeuticsKriya Therapeutics · NCT07596485 · 24 planned · Canada
Ahead
- Feb 2029Primary completion: phase 2 study in Trigeminal NeuralgiaKriya Therapeutics · NCT07596485
TargetBeta
“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cytisinerule | Achieve Life Sciences | phase 3 | 13 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07596485Trigeminal Neuralgia · Canada | 2 | Recruiting | Kriya Therapeutics | Feb 2029 | 24 |
| NCT05576415Dry Eye Syndromes · China | 1 | Completed | Corxel Pharmaceuticals | Apr 27, 2023 | 9 |
| NCT05378945Dry Eye Syndromes · China | 3 | Completed | Corxel Pharmaceuticals | Apr 4, 2023 | 340 |
| NCT04957758Neurotrophic Keratopathy · United States | 2 | Completed | Viatris | Jan 27, 2023 | 113 |
| NCT04210180Smoking Cessation · United States | 3 | Completed | Rose Research Center | Oct 14, 2020 | 25 |
| NCT04072146Healthy Subjects · United States | 1 | Completed | Viatris | Nov 15, 2019 | 22 |
| NCT04036292Dry Eye Syndromes · United States | 3 | Completed | Viatris | Apr 10, 2020 | 758 |
| NCT04188106Smoking Cessation · United States | 4 | Completed | Rose Research Center | Dec 15, 2019 | 26 |
| NCT03873246Dry Eye Syndromes · Mexico | 2 | Completed | Viatris | Jan 7, 2020 | 123 |
| NCT03688802Dry Eye Syndromes · United States | 2 | Completed | Viatris | Sep 30, 2019 | 18 |
| NCT03636061Dry Eye Syndromes · United States | 2 | Completed | Viatris | Sep 26, 2018 | 182 |
| NCT01574703Smoking Cessation · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Jul 2015 | 4,595 |
| NCT01456936Smoking Cessation · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Jan 2015 | 8,144 |
| NCT01370356Smoking Cessation · United States, Australia, Canada and more | 4 | Completed | Pfizer | Jul 2013 | 1,510 |
| NCT01312909Smoking Cessation · United States, Canada, Georgia and more | 4 | Completed | Pfizer | Jan 2018 | 312 |
| NCT01244061Smoking Cessation · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 2012 | 498 |
| NCT01078298Smoking Cessation · United States, Bosnia and Herzegovina, Croatia and more | 4 | Completed | Pfizer | Jun 2012 | 525 |
| NCT00889720Smoking Cessation · France, Italy | 4 | Completed | Pfizer | Jul 2010 | 16 |
| NCT00749944Smoking Cessation · United States | 4 | Completed | Pfizer | Jul 2009 | 110 |
| NCT00744978Alzheimer Disease · Korea, Republic of | 2 | Completed | Pfizer | Nov 2010 | 66 |
| NCT00743847Schizophrenia | 2 | Withdrawn | Pfizer | Nov 2009 | 0 |
| NCT00717093Tobacco Use Cessation · Norway, Sweden | 4 | Completed | Pfizer | Apr 2009 | 432 |
| NCT00694044Healthy · United States | 1 | Completed | Pfizer | Jun 2008 | 50 |
| NCT00691483Smoking Cessation · United States, Argentina, Brazil and more | 4 | Completed | Pfizer | Sep 2009 | 659 |
| NCT00661765Smoking Cessation · United States | 1 | Completed | Pfizer | Jun 2008 | 18 |
| NCT00644969Smoking Cessation · United States, Canada | 3 | Completed | Pfizer | Apr 2010 | 128 |
| NCT00635401Smoking · Japan | 2 | Completed | Pfizer | 30 | |
| NCT00594204Smoking Cessation · Brazil, Colombia, Costa Rica and more | 4 | Completed | Pfizer | Jun 2009 | 593 |
| NCT00527150Smoking Cessation · United States | 1 | Completed | Pfizer | Feb 2008 | 48 |
| NCT00463918Smoking Cessation · United States, United Kingdom | 1 | Completed | Pfizer | 73 | |
| NCT00452894Smoking · China | 1 | Completed | Pfizer | 14 | |
| NCT00371813Smoking Cessation · China, Singapore, Thailand | 3 | Completed | Pfizer | 334 | |
| NCT00301145Unspecified Adult Solid Tumor, Protocol Specific · United States | – | Completed | SRI International | Jun 2008 | 1,200 |
| NCT00282984Smoking Cessation · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Nov 2007 | 714 |
| NCT00150254Smoking Cessation · United States | 2 | Completed | Pfizer | 625 | |
| NCT00150241Smoking Cessation · United States | 2 | Completed | Pfizer | 625 | |
| NCT00150228Smoking Cessation · United States | 2 | Completed | Pfizer | 300 | |
| NCT00143364Smoking Cessation · United States | 3 | Completed | Pfizer | 1,005 | |
| NCT00143325Smoking Cessation · United States, Belgium, France and more | 3 | Completed | Pfizer | 730 | |
| NCT00143299Smoking Cessation · United States, Australia | 3 | Completed | Pfizer | 375 | |
| NCT00143286Smoking Cessation · United States, Canada, Czech Republic and more | 3 | Completed | Pfizer | 2,000 | |
| NCT00141206Smoking Cessation · United States | 3 | Completed | Pfizer | 1,005 | |
| NCT00141167Smoking Cessation · Korea, Republic of, Taiwan | 3 | Completed | Pfizer | 250 | |
| NCT00139750Smoking Cessation · Japan | 2 | Completed | Pfizer | 600 |
How it is read
Names in the registry
- “varenicline”, 11 entries
- “Varenicline Tartrate”, 7 entries
- “Varenicline”, 6 entries
- “varenicline (CP-526,555)”, 6 entries
- “CP-526,555 (varenicline)”, 4 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 28 studies
- Dry Eye Syndromes, 6 studies
- Smoking, 2 studies
- Trigeminal Neuralgia, 1 study
- Cigarette Smoking, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.